Expressions of Stromal Cell Derived Factor-1 and Its Receptor CXCR4 in Patients with Aplastic Anemia, Myeloid Dysplasia Syndrome and Acute Myelocytic Leukemia
XU Li,ZHANG Qian-qiao,ZHANG Zheng,YANG Rui,SONG Lu-xi,GUO Fang,HE Yi-qing,YANG Si,CUI Lian,LI Xiao,CHANG Chun-kang
DOI: https://doi.org/10.16150/j.1671-2870.2010.05.030
2010-01-01
Abstract:Objective To investigate the role of stromal cell derived factor-1 (SDF-1) and its receptor CXCR4 in the pathogenesis of aplastic anemia (AA), myeloid dysplasia syndrome (MDS) and acute myelocytic leukemia (AML). Methods ELISA was used to determine the SDF-1 level in bone marrow supernatant and flow cytometry was used to measure the CXCR4 expressing CD34+cells in patients with AA, MDS, AML and controls (iron-deficiency anemia and deficiency anemia). Results The level of SDF-1 in bone marrow supernatant from patients with AML, AA, MDS and controls were 8125.0, 6429.5, 10816.2 and 8846.5 pg/mL, respectively. Statistically significant difference in level of SDF-1 was found between patients with AA and patients with MDS and low risk MDS (P=0.001,0.001), and no statistical significant difference was seen between patients with AML, AA, MDS and controls (P0.05). The percentages of CXCR4 expressing CD34 + cell in patients with AML, AA, MDS and controls were (11±16)%, (70±26)%, (32±31)% and (20±11)%, respectively. MDS patients were divided into low risk and high risk groups according to IPSS score, the percentages of CXCR4 expressing CD34+ cell in low risk and high risk MDS patients were (37±33)% and (15±17)%, respectively (P= 0.025). Conclusions Bone marrow micro-environment might play a negative feedback role to inhibit the progression of disease by regulating the level of CXCR4 expressing CD34+cells.